Nature Communications · 2022 · 74 citations · 73 references
PharmacyMedicinal ChemistryOncologyDrug DesignDrug DiscoveryProdrug DesignAnticancer Prodrug DesignNanomedicineTumor-activated ProdrugsAnticancer ActivityArtificial MetalloenzymesBioactivityBioactivity AssessmentCell-based Pharmacological AssaysMetallodrug DesignRing-closing MetathesisTumor-targeted Prodrugs
Considering the intrinsic toxicities of transition metals, their incorporation into drug therapies must operate at minimal amounts while ensuring adequate catalytic activity within complex biological systems. As a way to address this issue, this study investigates the design of synthetic prodrugs that are not only tuned to be harmless, but can be robustly transformed in vivo to reach therapeutically relevant levels. To accomplish this, retrosynthetic prodrug design highlights the potential of naphthylcombretastatin-based prodrugs, which form highly active cytostatic agents via sequential ring-closing metathesis and aromatization. Structural adjustments will also be done to improve aspects related to catalytic reactivity, intrinsic bioactivity, and hydrolytic stability. The developed prodrug therapy is found to possess excellent anticancer activities in cell-based assays. Furthermore, in vivo activation by intravenously administered glycosylated artificial metalloenzymes can also induce significant reduction of implanted tumor growth in mice.
73
Engineering new catalytic activities in enzymes
Kai Chen, Frances H. Arnold · Nature Catalysis · 2020 · 865 citations
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Marc Hafner, Mario Niepel, Mirra Chung et al. · Nature Methods · 2016 · 741 citations · Full text
Medicine, Oncology, Pharmacology +11
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
G. Dark, S A Hill, Vivien E. Prise et al. · PubMed · 1997 · 624 citations
Medicine, Oncology, Pharmacology +13